James Burns
CEO

Phenomics Health is a bioinformatics platform that integrates genomic and phenotypic data to create personalized treatment plans for patients. The platform enhances therapeutic outcomes by providing insights tailored to individual biological profiles, addressing the inefficacy of standard treatment approaches.
Raised to date
$11.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

CEO
Medication management is challenging due to variability in patient genetics, adherence, and drug interactions, leading to ineffective treatments and adverse drug events. A significant percentage of prescribed medications are ineffective or not taken as prescribed, resulting in suboptimal patient outcomes and increased healthcare costs. Traditional approaches often fail to account for individual biological differences, leading to a trial-and-error approach to prescribing.
Phenomics Health offers a precision medicine solution that combines pharmacogenomics (PGx) and pharmacometabolomics (PMx) to predict the right drug and measure the right dose for individual patients. The platform uses genetic testing to predict drug response based on a patient's genetic factors and direct measurement of medication levels in the patient's circulation to monitor drug adherence, polypharmacy, and drug-drug interactions. By integrating these approaches, Phenomics Health aims to personalize medication treatment plans, optimize therapeutic effectiveness, and reduce the risk of adverse events. The platform provides clinicians with insights into a patient's unique biological profile, enabling more informed prescribing decisions and improved patient outcomes.
The primary target audience includes healthcare providers, such as physicians and pharmacists, seeking to optimize medication management for their patients, as well as patients with complex therapeutic regimens or those at high risk for adverse drug events.